BioMérieux is deploying consultants to advise hospitals about the most optimal testing options and how to implement them.

As a longer-term product, the firm is developing a sequencing test for the clinic that could enable identifying a broad range of sepsis pathogens and detecting antimicrobial resistance.

Ortho Clinical Diagnostics is developing the assay for use on its Vitros systems for use by small-, mid-, and high-volume labs in managing sepsis.

The financing will go toward efforts by the German firm to bring its point-of-care screening system for drug-resistant bacteria to hospitals. 

The clearance provides clinicians in emergency departments, intensive care, and other hospital units with a tool for antibiotic stewardship.

Researchers from the University of Illinois said their test may one day enable patients to identify sepsis at home and transmit test results immediately to a physician. 

Thermo Fisher Scientific's PCT assay for the diagnosis of sepsis was among a few tests that received 510(k) clearance last month.  

The test measures quantities of white blood cells and CD64 on the surface of neutrophils, enabling the immune system's response to sepsis to be monitored. 

With CE marking for the gram-positive and gram-negative panels, the firm has achieved the designation for its family of three ePlex bloodstream infection assays.

The assay is the firm homogeneous PCT assay for use on Beckman Coulter AU model chemistry analyzers and can be used to manage bacterial infections and sepsis.